Unity Biotechnology, Inc. (UBX)
NASDAQ: UBX · Real-Time Price · USD
2.003
+0.213 (11.92%)
Jan 22, 2025, 2:09 PM EST - Market open
Unity Biotechnology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Unity Biotechnology stock have an average target of 7.00, with a low estimate of 6.00 and a high estimate of 8.00. The average target predicts an increase of 249.42% from the current stock price of 2.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UBX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +199.51% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +299.34% | Aug 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +299.34% | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +299.34% | Apr 16, 2024 |
| Wedbush | Wedbush | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Nov 16, 2023 |
Financial Forecast
Revenue This Year
39.05M
Revenue Next Year
52.18M
from 39.05M
Increased by 33.62%
EPS This Year
-1.50
from -2.70
EPS Next Year
-1.73
from -1.50
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 121.8M | 162.8M | 134.4M | |||
| Avg | 39.1M | 52.2M | 45.3M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 316.7% | 157.6% | |||
| Avg | - | 33.6% | -13.2% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.55 | -1.79 | -0.62 | |||
| Avg | -1.50 | -1.73 | -0.84 | |||
| Low | -1.46 | -1.68 | -1.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.